InvestorsHub Logo

vator

12/04/22 9:18 AM

#543248 RE: PPHMVERYLONG #543241

Wow. Pseudo Progression is a phenomenon where the killer T cells load into the tumor giving it a false indication that the tumor is growing to do more damage. It enlarges because cells you want to attack the tumor are taken in. This was viewed in patients that got treatment who were not in the trial and in the Direct trial patients. PFS means little when you have actual OS data that this trial has collected.

br8k0ut

12/04/22 9:19 AM

#543249 RE: PPHMVERYLONG #543241

It's not just the people on this board that think the data is compelling. Did you not see the peer review? It includes oncology experts, the people that matter when it comes to those with cancer and it's subsequent treatment modalities, not the opinions of people on this board. Furthermore, if the crooked FDA will approve Aduhelm, whose efficacy is questionable, why would they not approve DC-vaxL , whose efficacy is proven?

Dr Bala

12/04/22 10:31 AM

#543285 RE: PPHMVERYLONG #543241

1. Total nonsense. Read the JAMA article.
2. The management is old. Can't say one way or the other.

hope4patients

12/04/22 10:35 AM

#543289 RE: PPHMVERYLONG #543241

JV or buyout coming. Absolutely no way to stop the train now. And that’s a great thing for patients and investors.